Shareprice
22 Apr 2025

About

FluoGuide A/S is a clinical stage biotechnology company focused on developing drugs for maximizing surgical outcomes by making cancer fluorescent.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

About FluoGuide

FluoGuide, founded in 2018, is a biotech company specializing in precision cancer surgery to improve patient outcomes. The company’s lead product, FG001, enhances surgical accuracy by illuminating cancer tissue intraoperatively using fluorescent light. By enabling more precise tumor removal, FG001 aims to reduce the risk of local recurrence, minimize surgical complications, and lower overall healthcare costs.

FG001 has demonstrated clinical benefit in aggressive brain cancer (high-grade glioma) by successfully guiding surgeons to remove additional cancerous tissue in all patients studied. Additionally, FG001 has proven effective in lung and head & neck cancers, with scientific literature suggesting potential applicability across a broad range of solid tumor types.

Beyond improving surgical precision, FG001 also functions as a photosensitizer, offering potential therapeutic applications through photothermal and photodynamic therapy. FluoGuide has secured strategic partnerships, including collaborations with Intuitive Surgical for robotic-assisted surgery and a laser system manufacturer to advance FG001’s therapeutic potential.

Listed on the Nasdaq First North Growth Market in Sweden, FluoGuide is committed to transforming cancer surgery and expanding its pipeline to address multiple cancer indications.

Learn more about our uPAR-based technology platform and our lead product FG001